An online survey among convalescents 5 months post SARS-CoV-2 infection in China

The effects of severe acute respiratory syndrome coronavirus 2(SARS‐CoV‐2)infection persist months and years after recovery.We conducted an online survey to assess the health condition of convalescents approximately 5 months following the primary infection of SARS‐CoV‐2.The study recruited 5,510 individuals who were primary infected,626 participants who had experienced reinfection,and 521 participants who were without infective history.The most common disorders after the primary infection group were fatigue(15.18%),memory issue(13.13%),post‐exertional malaise(PEM,11.68%),and brain fog(11.29%)at the time of survey.In addition,SARS‐CoV‐2 infection had an impact on the reproductive systems.In stepwise logistic regression analysis,smoking currently,with background diseases,and outpatient visits in the acute phase could be associated with moderate/severe disorders.Further analysis of different background diseases showed that allergic rhinitis,hyperlipidemia,cardiovascular disease,autoimmune diseases,neurological diseases,and asthma likely increased the risk of moderate/severe disorders.The probability of developing disorders of individuals with SARS‐CoV‐2 reinfection was higher before the secondary infection than uninfected people.Fatigue,PEM,muscle pain/spasms,chills,joint pain,excessive sweating at rest,headache/dizziness,sore throat or foreign body sensation in the throat,cough,expectoration,dry/painful/watery eyes,loss of appetite and constipation were associated with an increased risk of reinfection.It was essential to undertake further research with enhanced randomization in a larger sample in the community,and to strengthen the validation of the research conclusions.The findings of this study contribute to a deeper understanding of the health recovery process among coronavirus disease 2019(COVID‐19)convalescents.Moreover,the findings help identify characteristic health risk factors associated with convalescents and highlight the risk of moderate/severe disorders and reinfection.Furthermore,the findings also provide valuable guidance and reference for SARS‐CoV‐2 rehabilitation strategies and the prevention of reinfection,offering insights for scientific recommendations。

Myocarditis and pericarditis following mRNA vaccination in autoimmune inflammatory rheumatic disease patients: A single‐center experience

Introduction:The mRNA vaccines Comirnaty(Pfizer/BioNTech)and Spikevax(Moderna)are considered safe and highly effective against SARS‐COV2.However,they are also associated with a small increased risk of pericarditis and myocarditis.There is concern about an increased risk of these complications in patients with autoimmune inflammatory rheumatic diseases(AIRD).Case Report:We describe three patients with pre‐existing AIRD who developed myocarditis or pericarditis shortly after receiving their first dose of the Pfizer‐BioNTech vaccine.The first case is a 31‐year‐old female with systemic lupus erythematosus(SLE)and anti‐phospholipid syndrome(APLS)who presented 7 days after receiving the Pfizer‐BioNTech vaccine and was diagnosed with myopericarditis following a positive troponin and abnormal transthoracic echocardiogram(TTE).The second case is a 29‐year‐old man with seronegative inflammatory arthritis and APLS who presented 7 days after receiving the first dose of the Pfizer‐BioNTech vaccine.His troponin and TTE were unremarkable however his ECG showed widespread ST elevation.Lastly,the third case is a 34‐year‐old man with Behcet's disease with a history of recurrent pericarditis.He developed a recurrence of symptoms approximately 7 days after his Pfizer‐BioNTech vaccine and self‐commenced prednisolone at home.He had normal laboratory and radiological findings.All patients received prednisolone resulting in a quick recovery and resolution of symptoms.Discussion:In this review we discuss the association between myocarditis,pericarditis and mRNA COVID‐19 vaccines,those who are at greatest risk and current clinical considerations.We also discuss the possible increased risk in AIRD patients and the current research supporting this.